Vin Ryu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vin Ryu has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Bo-Hyun Yoon
Department of Psychiatry, Naju National Hospital, Naju, Korea
9 shared publications - Chan-Mo Yang
Department of Psychiatry, Wonkwang University Hospital, Iksan, Republic of Korea
9 shared publications - Duk-In Jon
Department of Psychiatry, Dong-A University Hospital, Busan, Korea
9 shared publications - Hyun-Ju Yang
Department of Psychiatry, Jeju National University College of Medicine, Jeju, Republic of Korea
9 shared publications - Jeong Seok Seo
Department of Psychiatry, Gwangmyeong Hospital, College of Medicine, Chung-Ang University, Gwangmyeong, Korea
9 shared publications - Jong-Hyun Jeong
Department of Psychiatry, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
9 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
Korean Medication Algorithm Project for Bipolar Disorder 2026: Comparisons with Other Treatment Guidelines
Won-Seok Choi, Jong-Hyun Jeong, Young Sup Woo, Won-Myong Bahk, Bo-Hyun Yoon, Won Kim, Sung-Yong Park, Jeong Seok Seo, Chan-Mo Yang, Sung-Hoon Yoon, Vin Ryu, Duk-In Jon, Nak-Young Kim, MoonSoo Lee, Hyun-Ju Yang, Young-Eun Jung, Moon-Doo Kim. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.26.1498
- 30 September 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Comparisons with Other Treatment Guidelines
Won-Seok Choi, Jong-Hyun Jeong, Young Sup Woo, Won-Myong Bahk, Bo-Hyun Yoon, Won Kim, Sung-Yong Park, Jeong Seok Seo, Chan-Mo Yang, Sung-Hoon Yoon, Vin Ryu, Duk-In Jon, Nak-Young Kim, MoonSoo Lee, Hyun-Ju Yang, Young-Eun Jung, Moon-Doo Kim. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.26.1498
- Open Access
- 28 August 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 864-879
Korean Medication Algorithm Project for Bipolar Disorder 2026, Sixth Revision: An Executive Summary
Hyun-Ju Yang, Young Sup Woo, Won-Myong Bahk, Jong-Hyun Jeong, Bo-Hyun Yoon, Won Kim, Sung-Yong Park, Jeong Seok Seo, Chan-Mo Yang, Sung-Hoon Yoon, Vin Ryu, Duk-In Jon, Nak-Young Kim, Won-Seok Choi, MoonSoo Lee, Young-Eun Jung, Moon-Doo Kim. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.26.1490
- 28 August 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 864-879
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026, Sixth Revision: An Executive Summary
Hyun-Ju Yang, Young Sup Woo, Won-Myong Bahk, Jong-Hyun Jeong, Bo-Hyun Yoon, Won Kim, Sung-Yong Park, Jeong Seok Seo, Chan-Mo Yang, Sung-Hoon Yoon, Vin Ryu, Duk-In Jon, Nak-Young Kim, Won-Seok Choi, MoonSoo Lee, Young-Eun Jung, Moon-Doo Kim. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.26.1490
- Open Access
- 25 July 2026
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 23 (7) , 837-850
Development of a Machine Learning-Based Model for Classifying Depression Using Physiological and Psychological Indicators
Objective This study aimed to develop and evaluate machine learning-based models for classifying depression symptoms using salivary hormone markers (cortisol and dehydroepiandrosterone [DHEA]) and psychological indicators from depression screening devices, and to determine the extent to which salivary hormone markers contribute to depression symptom classification.Methods Two models were developed, a multi-class classification (four degrees of depression) and a binary classification model (normal vs. depression), using psychological indicators that assess depression symptoms, protective and vulnerability factors, and physiological indicators including salivary cortisol and DHEA. Each model was evaluated both with and without physiological indicators. Data from 368 individuals were used for model training, with 92 individuals reserved for independent testing. Out of 36 variables, including psychological indicators from the PROtective and Vulnerable factors battEry test and physiological markers (e.g., salivary cortisol and DHEA), 24 non-demographic variables with independent contributions were selected, excluding demographic information. To ensure model robustness, overfitting risks were mitigated using k-fold cross-validation, class weight balancing, and grid search optimization. Model performance was evaluated based on accuracy, precision, recall, and receiver operating characteristic values.Results The multi-class classification model achieved 85.9% and 76.1% accuracy with and without physiological indicators, respectively. The binary classification model (depression presence or absence) achieved 97.8% accuracy both with and without physiological indicators.Conclusion The machine learning models demonstrated high accuracy in depression classification, showing a noteworthy improvement in classification performance when integrating psychological and physiological markers. Future clinical trials will be conducted to secure additional clinical data to verify the model’s reliability and clinical validity.
- 25 July 2026
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 23 (7) , 837-850
Open AccessDevelopment of a Machine Learning-Based Model for Classifying Depression Using Physiological and Psychological Indicators
Objective This study aimed to develop and evaluate machine learning-based models for classifying depression symptoms using salivary hormone markers (cortisol and dehydroepiandrosterone [DHEA]) and psychological indicators from depression screening devices, and to determine the extent to which salivary hormone markers contribute to depression symptom classification.Methods Two models were developed, a multi-class classification (four degrees of depression) and a binary classification model (normal vs. depression), using psychological indicators that assess depression symptoms, protective and vulnerability factors, and physiological indicators including salivary cortisol and DHEA. Each model was evaluated both with and without physiological indicators. Data from 368 individuals were used for model training, with 92 individuals reserved for independent testing. Out of 36 variables, including psychological indicators from the PROtective and Vulnerable factors battEry test and physiological markers (e.g., salivary cortisol and DHEA), 24 non-demographic variables with independent contributions were selected, excluding demographic information. To ensure model robustness, overfitting risks were mitigated using k-fold cross-validation, class weight balancing, and grid search optimization. Model performance was evaluated based on accuracy, precision, recall, and receiver operating characteristic values.Results The multi-class classification model achieved 85.9% and 76.1% accuracy with and without physiological indicators, respectively. The binary classification model (depression presence or absence) achieved 97.8% accuracy both with and without physiological indicators.Conclusion The machine learning models demonstrated high accuracy in depression classification, showing a noteworthy improvement in classification performance when integrating psychological and physiological markers. Future clinical trials will be conducted to secure additional clinical data to verify the model’s reliability and clinical validity.
- Open Access
- 10 March 2026
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 69 (3) , 217-227
Trends in pharmacotherapy and guideline comparisons in bipolar disorder: a narrative review
Purpose: This article summarizes the clinical presentation, importance of early diagnosis, pharmacological strategies, psychosocial interventions, and future perspectives of bipolar disorder. It also emphasizes the need for evidence-based multidisciplinary approaches to this chronic mental illness, which has a rising global lifetime prevalence of approximately 0.5%. This review provides a comprehensive overview addressing diagnostic delays (averaging 5–10 years) and comorbidities.Current concepts: Clinically, bipolar disorder is classified into types 1 and 2 and is characterized by recurrent mania/hypomania, depression, and mixed states. Common psychiatric comorbidities (e.g., anxiety disorders) and physical comorbidities (e.g., cardiovascular disease) contribute to diagnostic delays. Challenges in early diagnosis stem from the absence of biomarkers; however, emerging trends include digital health tools (smartphone apps, wearables) and precision psychiatry integrating genetic and neuroimaging data. Core pharmacological treatments include mood stabilizers (lithium, valproate), atypical antipsychotics (quetiapine, aripiprazole), and selective antidepressants. Combination therapy is used for manic episodes, with cautious antidepressant use in depressive episodes to minimize switch risk. Guideline comparisons reveal regional differences and debate on antidepressant efficacy versus risks. Regarding psychosocial interventions, cognitive-behavioral therapy, psychoeducation, and family therapy are effective for relapse prevention, with digital integration representing a forward-looking approach.Discussion and conclusion: Multidisciplinary integration of pharmacological and psychosocial interventions is essential for improving outcomes in bipolar disorder. Promising directions include novel drugs (NRX-101, lumateperone), gene therapy, artificial intelligence-driven personalization, and efforts to address global disparities. However, developing early diagnostic tools and harmonizing guidelines remain key challenges. Evidence-based strategies can minimize relapse and improve quality of life.
- 10 March 2026
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 69 (3) , 217-227
Open AccessTrends in pharmacotherapy and guideline comparisons in bipolar disorder: a narrative review
Purpose: This article summarizes the clinical presentation, importance of early diagnosis, pharmacological strategies, psychosocial interventions, and future perspectives of bipolar disorder. It also emphasizes the need for evidence-based multidisciplinary approaches to this chronic mental illness, which has a rising global lifetime prevalence of approximately 0.5%. This review provides a comprehensive overview addressing diagnostic delays (averaging 5–10 years) and comorbidities.Current concepts: Clinically, bipolar disorder is classified into types 1 and 2 and is characterized by recurrent mania/hypomania, depression, and mixed states. Common psychiatric comorbidities (e.g., anxiety disorders) and physical comorbidities (e.g., cardiovascular disease) contribute to diagnostic delays. Challenges in early diagnosis stem from the absence of biomarkers; however, emerging trends include digital health tools (smartphone apps, wearables) and precision psychiatry integrating genetic and neuroimaging data. Core pharmacological treatments include mood stabilizers (lithium, valproate), atypical antipsychotics (quetiapine, aripiprazole), and selective antidepressants. Combination therapy is used for manic episodes, with cautious antidepressant use in depressive episodes to minimize switch risk. Guideline comparisons reveal regional differences and debate on antidepressant efficacy versus risks. Regarding psychosocial interventions, cognitive-behavioral therapy, psychoeducation, and family therapy are effective for relapse prevention, with digital integration representing a forward-looking approach.Discussion and conclusion: Multidisciplinary integration of pharmacological and psychosocial interventions is essential for improving outcomes in bipolar disorder. Promising directions include novel drugs (NRX-101, lumateperone), gene therapy, artificial intelligence-driven personalization, and efforts to address global disparities. However, developing early diagnostic tools and harmonizing guidelines remain key challenges. Evidence-based strategies can minimize relapse and improve quality of life.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (3) , 219-233
Korean Medication Algorithm Project for Bipolar Disorder 2026: Children and Adolescents
양찬모, et al. J Korean Neuropsychiatr Assoc. 2026 Aug;65(3):219-233. https://doi.org/10.4306/jknpa.2026.65.3.219
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (3) , 219-233
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Children and Adolescents
양찬모, et al. J Korean Neuropsychiatr Assoc. 2026 Aug;65(3):219-233. https://doi.org/10.4306/jknpa.2026.65.3.219
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (3) , 210-218
Korean Medication Algorithm Project for Bipolar Disorder 2026: Rapid Cycling
윤성훈, et al. J Korean Neuropsychiatr Assoc. 2026 Aug;65(3):210-218. https://doi.org/10.4306/jknpa.2026.65.3.210
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (3) , 210-218
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Rapid Cycling
윤성훈, et al. J Korean Neuropsychiatr Assoc. 2026 Aug;65(3):210-218. https://doi.org/10.4306/jknpa.2026.65.3.210
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (3) , 200-209
Korean Medication Algorithm Project for Bipolar Disorder 2026: Maintenance Therapy
유빈, et al. J Korean Neuropsychiatr Assoc. 2026 Aug;65(3):200-209. https://doi.org/10.4306/jknpa.2026.65.3.200
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (3) , 200-209
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Maintenance Therapy
유빈, et al. J Korean Neuropsychiatr Assoc. 2026 Aug;65(3):200-209. https://doi.org/10.4306/jknpa.2026.65.3.200
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (2) , 96-107
Korean Medication Algorithm Project for Bipolar Disorder 2026: Overview
김원, et al. J Korean Neuropsychiatr Assoc. 2026 May;65(2):96-107. https://doi.org/10.4306/jknpa.2026.65.2.96
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (2) , 96-107
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Overview
김원, et al. J Korean Neuropsychiatr Assoc. 2026 May;65(2):96-107. https://doi.org/10.4306/jknpa.2026.65.2.96
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (2) , 122-130
Korean Medication Algorithm Project for Bipolar Disorder 2026: Depressive Episode
정영은, et al. J Korean Neuropsychiatr Assoc. 2026 May;65(2):122-130. https://doi.org/10.4306/jknpa.2026.65.2.122
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (2) , 122-130
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Depressive Episode
정영은, et al. J Korean Neuropsychiatr Assoc. 2026 May;65(2):122-130. https://doi.org/10.4306/jknpa.2026.65.2.122
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (2) , 108-121
Korean Medication Algorithm Project for Bipolar Disorder 2026: Manic Episode
최원석, et al. J Korean Neuropsychiatr Assoc. 2026 May;65(2):108-121. https://doi.org/10.4306/jknpa.2026.65.2.108
- 1 January 2026
- Published by XMLink in Journal of Korean Neuropsychiatric Association
- Vol. 65 (2) , 108-121
Open AccessKorean Medication Algorithm Project for Bipolar Disorder 2026: Manic Episode
최원석, et al. J Korean Neuropsychiatr Assoc. 2026 May;65(2):108-121. https://doi.org/10.4306/jknpa.2026.65.2.108